Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis

Bibliography

• Ardizzone S. Ulcerative colitis. Orphanet Encylopedia Sept 2003
   Google Scholar
• Sood A, Midha V, Sood N, et al. Incidence and prevalence of ulcerative colitis in Punjab, north India. Gut 2003;52(11):1587-90
   PubMed Web of Science ®Google Scholar
• Orholm M, Binder V, Sørensen TI, et al. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000;35(10):1075-81
   PubMed Web of Science ®Google Scholar
• Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992;33(7):938-41
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130(4):1030-8
   PubMed Web of Science ®Google Scholar
• Svartz N. Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis B. Therapeutic results in ulcerative colitis C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Med Scand 1942;110:557-90
   Google Scholar
• Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. J Pharmacol Exp Ther 1972;181:555-62
   PubMed Web of Science ®Google Scholar
• Van Hees PAM, Bakker JH, Tongreren JHM. Effects of sulfapyridine, 5-aminosalycilic acid, and placebo in patients with idiopathic proctitis: a study to determinethe active therapeutic moiety of sulfasalazine. Gut 1980;21:632-5
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Boughton-Smith NK, Whittle BJ. Modulation of human colonicarachidonic acid metabolism by sulfasalazine. Dig Dis Sci 1985;30:1161
   PubMed Web of Science ®Google Scholar
• Ligumsky M, Karmeli F, Sharon P, et al. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981;81:444
   PubMed Web of Science ®Google Scholar
• Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990;343:278
   PubMed Web of Science ®Google Scholar
• Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin 2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995;272:399
   PubMed Web of Science ®Google Scholar
• Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003:CD000543
   Google Scholar
• Green JR, Swan CH, Gibson JA, et al. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study. Aliment Pharmacol Ther 2004;19:435-42
   PubMed Web of Science ®Google Scholar
• Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colits. Am J Gastroenterol 2002;97(12):3078-86
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009;54(4):712-21. [Epub 6 Aug 2008]
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.Med Sci Monit 2004;10(11):PI126-31. [Epub 26 Oct 2004]
   PubMed Web of Science ®Google Scholar
• Schwab M, Reynders V, Loitsch S, et al. PPAR gamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells
   Google Scholar
• Hanauer SB, Smith M. Critical drug appraisal: Olsalazine. Drug Ther Bull 1991;21:57
   Google Scholar
• Nikfar S, Rahimi R, Rezaie A, Abdollahi M. Meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and the maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54(6):1157-70
   PubMed Web of Science ®Google Scholar
• Woltsche M, Woltseche-Kaur I, Roeger GM, Aberer W. Sulfasalazine-induced extrinsic allergic alveolitis in a patient with psoriatic arthritis. Eur J Med Res 2001;6:495
   PubMed Web of Science ®Google Scholar
• World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalamine-associated interstitial nephritis. Nephrol Dial Transplant 1996;11:614
   PubMed Web of Science ®Google Scholar
• Frandsen NE, Saugmann S, Marcussen N. Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron 2002;92(1):200-2
   PubMedGoogle Scholar
• Tadic M, Grgurevic I, Scukanec-Spoljar M, et al. Acute interstitial nephritis due to mesalazine. Nephrology (Carlton) 2005;10(2):103-5
   PubMed Web of Science ®Google Scholar
• Netzer P. Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease. Schweiz Med Wochenschr 1995;125(50):2438-42
   PubMedGoogle Scholar
• Robertson E, Austin D, Jamieson N, Hogg K. Balsalazide-induced myocarditis. Int J Cardiol 2008;130(3):e121-e122
   PubMedGoogle Scholar
• Ishikawa N, Imamura T, Nakajima K, et al. Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis. Intern Med 2001;40(9):901-4
   PubMed Web of Science ®Google Scholar
• Waite RA, Malinowski JM. Possible mesalamine-induced pericarditis: case report and literature review. Pharmacotherapy 2002;22(3):391-4
   PubMed Web of Science ®Google Scholar
• de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007;102(12):2747-53. [Epub 31 Aug 2007]
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008;25(2):271-5. [Epub 4 Dec 2007]
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Brabant G, Gubler M-C, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994;344:620-1
   PubMed Web of Science ®Google Scholar